Loading...

News List

NASH新药Kylo-0603在中国临床I期完成首例受试者给药

2023-04-09


2023年3月28日,上海赫吉亚生物医药有限责任公司自主研发的针对非酒精性脂肪性肝炎(NASH)适应症的甲状腺素受体-β(THR-β)激动剂药物Kylo-0603,在浙江大学医学院附属第一医院顺利完成I期临床试验首例人体给药。

该研究(CTR20230472)是一项在健康受试者中单次、多次给药的I期剂量爬坡临床研究。其主要目的是评估中国健康受试者接受Kylo-0603单次和多次给药后的药代动力学(PK)特征、安全与耐受性及食物影响,以支持Kylo-0603在非酒精性脂肪性肝炎(NASH)等适应症的后续临床开发。


Pre: China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage

Next: The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.